Zimmer Biomet Q3 FY2026 results
$103.21−1.29%
Zimmer Biomet reported revenue of $2.06 billion, up 3.1% from a year earlier, net income of $192 million and diluted earnings per share of $1.00 against $1.16 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).
From its quarterly report, filed 4 Nov 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $2.06B | $2.00B | +3.1% |
| Gross profit | $1.47B | $1.44B | +1.8% |
| Gross margin | 71.2% | 72.1% | −0.9 pts |
| Operating income | $307.6M | $351.3M | −12.4% |
| Operating margin | 14.9% | 17.6% | −2.6 pts |
| Net income | $191.6M | $230.9M | −17.0% |
| Diluted EPS | $1.00 | $1.16 | −13.8% |
| Operating cash flow | $560.0M | $418.7M | +33.7% |
| Capital expenditure | $75.80M | $55.00M | +37.8% |
| Free cash flow | $484.2M | $363.7M | +33.1% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| Knees revenue | $767.5M | down 3.1% |
| S.E.T revenue | $578.3M | up 6.8% |
| Hips revenue | $536.5M | up 6.0% |
| Technology & Data, Bone Cement and Surgical revenue | $180.6M | up 12.0% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $2.06B | +3.1% | $1.00 |
| Q2 FY2026 | 30 Jun 2026 | $2.18B | +4.8% | $1.03 |
| Q1 FY2026 | 31 Mar 2026 | $2.09B | +9.3% | $1.22 |
| Q4 FY2025 | 31 Dec 2025 | $2.24B | +10.9% | $0.70 |
| Q3 FY2025 | 30 Sep 2025 | $2.00B | +9.7% | $1.16 |
| Q2 FY2025 | 30 Jun 2025 | $2.08B | +7.0% | $0.77 |
| Q1 FY2025 | 31 Mar 2025 | $1.91B | +1.1% | $0.91 |
| Q4 FY2024 | 31 Dec 2024 | $2.02B | +4.3% | $1.20 |
More on Zimmer Biomet: financial statements · revenue · earnings per share
ZBH's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.
